MedTrace Logo

Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301

NCT01536353 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-11-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the bioavailability and safety of AGSAV301 tablet in healthy male volunteers.

Conditions

Interventions

DRUG

AGSAV301

tablet, q.d.

DRUG

Exforge 10/160

Tablet, q.d.

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Kyun-Seop Bae, M.D., Ph.D. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-04-30
Completion
2012-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536353 on ClinicalTrials.gov